See the DrugPatentWatch profile for Asfotase
What is asfotase alfa (Strensiq) and what would a “biosimilar” mean?
Asfotase alfa (marketed as Strensiq) is an enzyme replacement therapy used for X-linked hypophosphatemia (XLH) and other forms of hypophosphatasia that are caused by loss of function in the ALPL gene. The drug provides functional tissue-nonspecific alkaline phosphatase to help improve bone mineralization and reduce complications related to low alkaline phosphatase activity.
A biosimilar to asfotase alfa would be designed to be highly similar to the reference biologic (Strensiq) in terms of structure, biologic activity, efficacy, and safety, with regulatory evidence to support that similarity. Whether a given product is approved as a biosimilar depends on the jurisdiction’s evaluation and labeling.
Has a biosimilar to Strensiq (asfotase alfa) been approved?
The answer depends on country and the latest regulatory decisions. I don’t have enough provided source information here to confirm whether an asfotase alfa biosimilar (or interchangeable product) is approved in your country, or what its brand name would be.
If you tell me the country (e.g., US, EU, UK, Canada, Australia, India), I can narrow the answer to approvals and how the product is labeled there.
How do asfotase alfa biosimilars typically get approved?
In general, biosimilars are approved through a stepwise “comparability” approach in which developers show:
- analytical similarity (structure and biochemical activity),
- functional similarity (pharmacodynamic and/or mechanism-related assays),
- and clinical similarity (often including at least one PK/PD study and safety/efficacy confirmation).
Exact requirements and study design can vary by regulator (EMA/CHMP vs FDA vs others), but the goal is to demonstrate no clinically meaningful differences from the reference product.
What should patients ask the prescriber if a biosimilar is available?
Patients usually want clarity on:
- whether the product is biosimilar to Strensiq specifically (not a different asfotase alfa formulation),
- how it will be substituted in practice (automatic interchange vs physician-controlled switching),
- expected monitoring (bone markers, growth and skeletal imaging, adverse effects),
- and whether any past response to Strensiq changes after switching.
These questions matter because even when biosimilars are approved, clinicians still manage treatment based on individual response and tolerability.
Is “Strensiq biosimilar” the same as “generic”?
No. Strensiq is a biologic (not a small-molecule drug), so it cannot have a typical “generic” pathway. A true biosimilar is a separately developed biologic with evidence of similarity; it is not identical in the way small-molecule generics are.
What about patents and when could biosimilars enter?
Biosimilar entry timing depends on patent expiry and regulatory exclusivity in the target country. Without the relevant jurisdiction and the patent/exclusivity status details, I can’t give a specific timeline for asfotase alfa/Strensiq.
If you share your country, I can describe the typical framework and what to check (reference product exclusivity, method-of-use patents, formulation/manufacturing patents).
If you mean a specific product name, what is it?
“Strensiq biosimilar” sometimes refers to:
- a locally marketed biosimilar with a different brand name, or
- a candidate in clinical trials (not yet approved).
If you provide the biosimilar candidate’s name (or a link/screenshot of the product you saw), I can help verify whether it is actually approved, what indication it covers, and whether it’s described as a biosimilar to asfotase alfa.
---
Sources
I don’t have any sources provided in your message to cite, and I don’t want to guess approval status or product names. Share your country (and any product name you’ve seen) and I’ll answer precisely with citations.